Science and Discovery

Drug Approval

3 articles

Pharmaceutical executives in a tense meeting with an FDA official, discussing the pause of a new drug approval voucher program.
Cosmos & Space

Drug companies ask FDA commissioner to pause new voucher program

Just months after its announcement, the FDA's Commissioner’s National Priority Voucher Program (CNPV), designed to slash drug approval times to as little as one month, is already facing calls from maj

Marcus Cole·June 5, 2026
A glowing vial of experimental Ebola therapy in a sterile lab, with a medical professional in the background, representing a critical public health response.
Cosmos & Space

HHS Authorizes Experimental Ebola Therapy for High-Risk Exposures

The U.S. Department of Health and Human Services (HHS) has authorized an experimental monoclonal antibody treatment, MBP-134, for Americans facing high-risk Ebola exposures. This move sidesteps tradit

Marcus Cole·June 5, 2026
FDA advisory panel in a hearing room, with a split decision on AstraZeneca's breast cancer drug, casting uncertainty for patients.
Health & Medicine

FDA advisory panel rejects AstraZeneca breast cancer drug

A U.S. Food and Drug Administration advisory committee voted 3 to 6 against the benefit-risk profile of AstraZeneca's breast cancer drug camizestrant, according to AstraZeneca . This decision creates

Aram Sarkisian·May 22, 2026